Oragenics, Inc. (OGEN) Starts Presentation at LD Micro Main Event
Oragenics, Inc. (NYSE: OGEN) is focused on becoming a leader in novel antibiotics against infectious disease and on developing effective treatments for oral mucositis. Oragenics, Inc. has established two exclusive worldwide channel collaborations with Intrexon Corporation and its subsidiaries. The collaborations allows Oragenics to accelerate the development of much needed new antibiotics that can work against resistant strains of bacteria and the development of biotherapeutics for oral mucositis and other diseases and conditions of the oral cavity, throat, and esophagus. For more information, visit the company's website at www.oragenics.com. About NetworkNewsWire NetworkNewsWire (NNW) is a financial news and content distribution…







